Stratosvir

Stratosvir is an early-stage biotech leveraging engineered oncolytic viruses to treat solid tumors, with a specific platform aimed at overcoming the critical barrier of systemic delivery. The company has attracted investment from cancer-focused organizations like Proven Connect (Prostate Cancer Research) and received an Innovate UK R&D grant, indicating external validation. Led by a seasoned team with deep experience in virology, biotech, and oncology deal-making, Stratosvir is positioned to advance its platform from pre-clinical development towards clinical testing.

Proprietary viral engineering platform using "biological intelligence" to design oncolytic viruses optimized for systemic (intravenous) delivery. Aims to overcome immune clearance and enhance tumor-specific replication to destroy cancer cells and reprogram the immune system.

Stratosvir competes in the oncolytic virotherapy space with companies like Replimune, Turnstone Biologics, and DNAtrix, as well as with the approved therapy T-VEC (Imlygic). Its key differentiator is the explicit focus on engineering for systemic delivery, a major hurdle in the field where most therapies are administered via intratumoral injection.